Long-Term Outcomes of Patients With or Pancreatic Cancer Treated With Maintenance Rucaparib

This secondary analysis of a nonrandomized clinical trial assesses long-term survival and genomic variants associated with therapeutic resistance in patients receiving maintenance rucaparib with , , or germline or somatic pathogenic variants and platinum-sensitive metastatic pancreatic adenocarcinoma.

Corresponding Author: Kim A. Reiss, MD, Perelman Center For Advanced Medicine, South Tower, 3400 Civic Center Blvd, 10th Floor, Philadelphia, PA 19104 (Kim.reissbinder@pennmedicine.upenn.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.